Sinopharm Accord Q1 2026 Preliminary Results Show Profit Decline Amid Stable Asset Base

Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Sinopharm Group Co ( (HK:1099) ) just unveiled an update. Sinopharm Group has released preliminary unaudited first-quarter 2026 figures for its Shenzhen-listed subsidiary Sinopharm Accord, showing a slight contraction in top-line performance alongside softer profitability metrics. The update offers investors an early view of the unit’s operating momentum and capital position, highlighting modest asset growth despite earnings pressure. For the three months to 31 March 2026, Sinopharm Accord’s revenue slipped 2.57% year on year to RMB 178.23 billion, while operating profit fell 14.24% and net profit attributable to shareholders declined 12.36%. Earnings per share eased to RMB 0.52 and weighted average return on equity narrowed by 0.31 percentage point, although total assets edged up 0.06% and equity attributable to shareholders increased 1.54%, supporting a small rise in net asset value per share. The most recent analyst rating on (HK:1099) stock is a Buy with a HK$22.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page. More about Sinopharm Group Co Sinopharm Group Co. Ltd. is a major Chinese pharmaceutical conglomerate with subsidiaries engaged in the distribution and retail of medicines and related healthcare products. Its subsidiary China National Accord Medicines Corporation Ltd. (Sinopharm Accord) is listed in Shenzhen with both A and B shares, focusing on pharmaceutical commerce and related services across mainland China. Average Trading Volume: 5,740,011 Technical Sentiment Signal: Strong Buy Current Market Cap: HK$65.03B For a thorough assessment of 1099 stock, go to TipRanks’ Stock Analysis page.